Pemitinib 13.5 mg (pemigatinib) Tablets

Pemitinib (Pemigatinib INN) is a targeted anticancer therapy belonging to FGFR inhibitor class. It is used in the management of specific types of advanced cancers where fibroblast growth factor receptor (FGFR) gene alterations are present.

Therapeutic Effects:

• Blocks abnormal FGFR signaling pathways responsible for cancer cell growth
• Helps slow down or stop tumor progression
• Reduces cancer cell proliferation in FGFR2 fusion-positive malignancies
• Supports disease control in previously treated advanced cancers

Primary Uses:

• Treatment of locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with FGFR2 gene rearrangement
• Used in adult patients after prior systemic therapy failure
• Targeted therapy for genetically selected cancer patients

Active Ingredient:

• Pemitinib 13.5 mg (Equivalent to Pemigatinib INN)

Dosage Form:

• Film-coated oral tablet

Inactive Ingredients (excipients may include):

• Tablet stabilizers
• Binding agents
• Coating materials
• Colorants (pharmaceutical grade)

Standard Adult Dose:

• Usually taken once daily in cycles (as prescribed by oncologist)

Administration Guidance:

• Take orally with water
• Can be taken with or without food
• Swallow whole, do not crush or chew
• Follow exact cycle schedule prescribed by physician

Missed Dose:

• If missed, take as soon as remembered unless next dose is near
• Do not double dose

Important Instructions:

• Must be used under strict oncology supervision
• Regular monitoring of liver function, kidney function, and electrolyte levels required
• Dose adjustment may be needed based on tolerance